USPTO Examiner SHIM DAVID M - Art Unit 1626

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19063141NOVEL COMPOUNDSFebruary 2025May 2025Allow200YesNo
19001374Arterial Application of Low Dose Ethyl Alcohol Enables Blood-Brain Barrier (BBB) Transient OpeningDecember 2024April 2025Allow300YesNo
18628560PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITORApril 2024January 2025Allow900YesNo
18597119Preparation method of glufosinate or derivatives thereofMarch 2024April 2025Allow1440YesYes
18591753NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORSFebruary 2024September 2024Allow710YesNo
18591965HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORSFebruary 2024March 2025Abandon1320NoNo
18432824METHODS AND MATERIALS FOR IMPROVING ARTERIOVENOUS FISTULA MATURATION AND MAINTAINING ARTERIOVENOUS FISTULA FUNCTIONALITYFebruary 2024October 2024Allow900YesNo
18420446FUSED RING COMPOUND HAVING UREA STRUCTUREJanuary 2024November 2024Allow1010NoNo
18392680FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASEDecember 2023April 2025Allow1610YesNo
185067625-(3-SUBSTITUTED PHENYL)-PYRIMIDO[4,5-d]PYRIMIDINE-2,4,7(1H,3H,8H)-TRIONE DERIVATIVES AS ANTICANCER AGENTSNovember 2023February 2024Allow310NoNo
18495213Crystal Form Of Pyrazolyl-Amino-Pyrimidinyl Derivative, And Preparation Method Therefor And Use ThereofOctober 2023July 2024Allow910YesNo
18483311GLP-1 Receptor Agonists and Uses ThereofOctober 2023March 2025Allow1810NoNo
18462780TRICYANOHEXANE PURIFICATION METHODSSeptember 2023June 2025Allow2200YesNo
18448150A LYOPHILIZED PHARMACEUTICAL COMPOSITIONAugust 2023November 2023Allow300YesNo
18346342Salts of Obicetrapib and Processes for their Manufacture and Intermediates ThereofJuly 2023March 2024Allow911YesNo
18265422LOX ENZYME INHIBITING METHODS AND COMPOSITIONSJune 2023February 2024Allow810NoNo
18315267IRAK DEGRADERS AND USES THEREOFMay 2023April 2024Abandon1101NoNo
18136765POLYMORPHISMS OF HM30181 MESYLATEApril 2023November 2024Allow1901YesNo
18134747PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATEApril 2023May 2024Allow1340YesNo
18134735PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATEApril 2023September 2023Allow501YesNo
18134894BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOFApril 2023August 2023Allow401YesNo
18126765PYRIDO[3,4-b]INDOL-1-ONE COMPOUNDS AS ANTIBACTERIAL AGENTSMarch 2023August 2023Allow400YesNo
18187487METHODS OF TREATING OPHTHALMIC CONDITIONS WITH ENHANCED PENETRATION COMPOSITIONS OF BIMATOPROST AND TIMOLOLMarch 2023May 2025Abandon2640NoNo
17967273PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASESOctober 2022April 2025Allow2901YesNo
17906946BUCCAL AND ENTERIC DELIVERY OF FATTY ACIDS IN FOODS AND BEVERAGESSeptember 2022May 2025Allow3100YesNo
17822494COMPOSITION FOR PREVENTING OR TREATING NEUROINFLAMMATORY DISEASES, COMPRISING CHLORPROMAZINEAugust 2022July 2024Abandon2320NoNo
17799950PRAMIPEXOLE HYDROCHLORIDE ORAL LIQUIDAugust 2022March 2023Allow700YesNo
17840532SYNERGISTIC COMPOSITION FOR ACTIVATING INTRACELLULAR SECONDARY MESSENGER(CAMP) PATHWAYJune 2022December 2024Allow3170YesNo
17831469FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOFJune 2022September 2023Allow1610NoNo
17752609COMBINATION THERAPIESMay 2022August 2024Allow2711YesNo
17735011ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDSMay 2022January 2024Allow2111NoNo
17727125COMPOUNDS FOR TREATING PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) MEDIATED DISEASES OR CONDITIONSApril 2022September 2023Abandon1701NoNo
17659558PHARMACOLOGICAL TREATMENT OF AUTISM SPECTRUM DISORDERApril 2022March 2024Abandon2310NoNo
17714298HETEROCYCLIC RED AZO COLORANTS FOR SEED TREATMENT APPLICATIONSApril 2022February 2025Allow3511NoNo
17710050N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOFMarch 2022January 2025Allow3421YesNo
17707297LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTSMarch 2022May 2023Allow1300YesNo
17689969Intraarterial (IA) Application of Low Dose of Ethyl Alcohol Enables Blood-Brain Barrier (BBB) Impermeable Therapeutics Brain EntryMarch 2022June 2025Allow4051YesNo
17683470COMBINATION THERAPY USING A MALT1 INHIBITOR AND A BTK INHIBITORMarch 2022July 2024Abandon2920YesNo
17638341CRYSTALLINE FORMS OF A CD73 INHIBITORFebruary 2022June 2025Abandon4001NoNo
17650555ANALGESIC FORMULATION FOR PERINEAL PAINFebruary 2022September 2023Abandon1911NoNo
17587565METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASEJanuary 2022February 2025Allow3741NoNo
17629899COCRYSTALS OF POSACONAZOLE, METHODS OF MAKING AND USING SAMEJanuary 2022June 2025Allow4001YesNo
17582728FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASEJanuary 2022April 2023Allow1500YesNo
17624970PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATEJanuary 2022March 2025Allow3811YesNo
17615437METHOD FOR SYNTHESIZING FUROIMIDAZOPYRIDINE COMPOUND, POLYMORPHIC SUBSTANCE AND POLYMORPHIC SUBSTANCE OF SALTNovember 2021March 2025Allow3901YesNo
17614921LIQUID COMPOSITION COMPRISING MEFENTRIFLUCONAZOLENovember 2021May 2025Abandon4201NoNo
17513284METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH VIRAL PROTEASE INHIBITORSOctober 2021March 2023Allow1700YesNo
17513448POLYMORPHISMS OF HM30181 MESYLATEOctober 2021March 2023Allow1700YesNo
17439638HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIASeptember 2021March 2025Allow4211YesNo
17427269INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITORJuly 2021December 2024Abandon4110NoNo
17288742COMPOSITIONS AND METHODS FOR TREATING GOUT AND HYPERURICEMIAApril 2021August 2024Abandon3910NoNo
17283724MALONATE SALT OF VARLITINIBApril 2021August 2024Abandon4011NoNo
17283646MST1 KINASE INHIBITOR AND USE THEREOFApril 2021February 2025Allow4621YesNo
17283151TYK2 KINASE INHIBITORSApril 2021August 2024Allow4110YesNo
17282277COVALENT TARGETING OF E3 LIGASESApril 2021June 2024Allow3901YesNo
17215959PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOFMarch 2021October 2023Allow3110YesNo
17280628CONDENSED-CYCLIC COMPOUNDMarch 2021July 2024Allow4001YesNo
17280211Combination of Acetylcholinesterase Inhibitor and 5-HT4 Receptor Agonist As Neuroprotective Agent In the Treatment of Neurodegenerative DiseasesMarch 2021February 2025Abandon4711NoNo
17213362CINNOLINE COMPOUNDS AND USES THEREOFMarch 2021December 2024Abandon4521NoNo
17279235NOVEL POLYMORPHS OF ACALABRUTINIB, A BRUTON'S TYROSINE KINASE INHIBITORMarch 2021April 2025Allow4921YesNo
17279394PREPARATION OF SEIMICARBAZIDE-SENSITIVE AMINE OXIDASE INHIBITOR AND USE THEREOFMarch 2021November 2024Allow4411YesNo
17277033NOVEL THIAZOLE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOFMarch 2021February 2024Allow3500NoNo
17273811METHODS OF TREATING MIGRAINEMarch 2021October 2024Abandon4310NoNo
17193410METHODS OF TREATING APOL-1 DEPENDENT FOCAL SEGMENTAL GLOMERULOSCLEROSISMarch 2021June 2023Allow2810YesNo
17192985BIARYL KINASE INHIBITORSMarch 2021April 2024Allow3710NoNo
17191220TARGETING HOMOLOGOUS RECOMBINATION FOR TREATING CANCERMarch 2021June 2025Abandon5240NoNo
17272924MORPHIC FORMS OF DANICOPANMarch 2021July 2023Allow2800YesNo
17186446PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITORFebruary 2021January 2024Allow3400YesNo
17272242APPLICATION OF ALLOPURINOL IN PREPARATION OF DRUG FOR TREATING CANCER WITH HIGH EXPRESSION OF PAICS GENEFebruary 2021September 2024Abandon4311NoNo
17271795CD73 INHIBITORSFebruary 2021October 2023Allow3201YesNo
17269817TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORSFebruary 2021June 2023Allow2800YesNo
17267631ASK1 INHIBITING AGENTSFebruary 2021January 2024Allow3500YesNo
17171385GLP-1 Receptor Agonists and Uses ThereofFebruary 2021May 2023Allow2700YesNo
17264940BIOAVAILABLE ORAL DOSAGE FORMSFebruary 2021July 2024Abandon4101NoNo
17265134NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITORFebruary 2021December 2023Allow3510YesNo
17151326METHOD FOR PREPARING ARTIFICIALLY SYNTHETIC (R,S)-NICOTINE SALTJanuary 2021August 2024Abandon4340NoNo
17260565Crystal form as ASK1 inhibitor and preparation method and application thereofJanuary 2021September 2023Allow3220YesNo
17260787ALKYNYL (HETERO) AROMATIC RING COMPOUNDS USED FOR INHIBITING PROTEIN KINASE ACTIVITYJanuary 2021April 2023Allow2710NoNo
17260547IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOFJanuary 2021August 2023Abandon3110NoNo
17260192BICYCLIC INHIBITORS OF HISTONE DEACETYLASEJanuary 2021November 2024Abandon4621NoYes
17258667N-(3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYLPHENYL)-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING KINASE-RELATED DISEASESJanuary 2021April 2023Allow2701YesNo
17258579DISINFECTANT COMPOSITIONJanuary 2021December 2024Abandon4720NoNo
17258051CRYSTALLINE SALT COMPRISING 5-METHYL-(6S)-TETRAHYDROFOLIC ACID AND 4-(2-HYDROXYETHYL)-MORPHOLINEJanuary 2021December 2022Allow2300YesNo
17257386COMPOSITIONS AND METHODS FOR TREATMENT OF ORAL ULCERATION AND ORAL MUCOSITISDecember 2020June 2025Abandon5421NoNo
17257262FUSED RING COMPOUND HAVING UREA STRUCTUREDecember 2020June 2023Allow3011NoNo
17254352METHODS OF TREATING CANCER USING A CLK INHIBITORDecember 2020May 2024Abandon4101NoNo
17254071TRICYCLIC PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATHDecember 2020March 2023Allow2710YesNo
16973995PROCESS FOR PREPARING CARBONATES BY ADDITION OF CO2 WITH AN EPOXIDEDecember 2020June 2024Abandon4210NoNo
16973723METHODS AND MATERIALS FOR IMPROVING ARTERIOVENOUS FISTULA MATURATION AND MAINTAINING ARTERIOVENOUS FISTULA FUNCTIONALITYDecember 2020November 2023Allow3501YesNo
17058681Method for Suppressing Freezing Damage and Composition for Preventing Freezing DamageNovember 2020July 2024Abandon4401NoNo
17055256FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESISNovember 2020August 2024Abandon4521NoNo
17050041Methods of Treating Excitotoxicity DisordersOctober 2020April 2024Abandon4201NoNo
17068053Moisturizing Liquid Composition With Cationic BiocideOctober 2020May 2025Allow5540YesNo
16989753TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICSAugust 2020August 2024Abandon4811NoNo
16987924METHOD OF TREATING CANCERAugust 2020June 2025Abandon5840YesYes
16964984NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDASE (hSEP) INHIBITORS TO REDUCE DETRIMENTAL EFFECTS OF PERFUSION DEFICIENCY OF PARENCHYMAL ORGANSJuly 2020May 2025Allow5850YesNo
167676645-(2,5-BIS(4-CHLORO-2-ISOPROPYLPHENYL)THIOPHEN-3-YL)-1H-TETRAZOLE FOR THE TOPICAL TREATMENT OF BACTERIAL INFECTIONSMay 2020March 2025Allow5820YesNo
16880717TRICYANOHEXANE PURIFICATION METHODSMay 2020June 2023Allow3711YesNo
16623948METHODS AND MEDICAL USESDecember 2019September 2024Abandon5741NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHIM, DAVID M..

Strategic Value of Filing an Appeal

Total Appeal Filings
2
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
2
(100.0%)
Filing Benefit Percentile
0.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SHIM, DAVID M. - Prosecution Strategy Guide

Executive Summary

Examiner SHIM, DAVID M. works in Art Unit 1626 and has examined 91 patent applications in our dataset. With an allowance rate of 65.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner SHIM, DAVID M.'s allowance rate of 65.9% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SHIM, DAVID M. receive 1.16 office actions before reaching final disposition. This places the examiner in the 19% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SHIM, DAVID M. is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +68.6% benefit to allowance rate for applications examined by SHIM, DAVID M.. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 28.6% of applications are subsequently allowed. This success rate is in the 42% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 11.8% of cases where such amendments are filed. This entry rate is in the 6% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Petition Practice

When applicants file petitions regarding this examiner's actions, 33.3% are granted (fully or in part). This grant rate is in the 26% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.